Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fluxome capital

This article was originally published in The Tan Sheet

Executive Summary

Copenhagen-based biotechnology firm Fluxome Sciences secured 100 million Danish krone ($21.3 million under the July 23 conversion rates) in its latest round of financing, the firm announces July 23. Claude J. Stoufs, senior investment manager for Fluxome shareholder Capricorn Venture Partners, says he anticipates the latest capital increase will help Fluxome "become a major player in the field of nutraceutical ingredients based on production by engineered microorganisms." In June, Fluxome announced a partnership with CP Kelco U.S., a division of J.M. Huber, to develop and commercialize fermentation-derived resveratrol for the dietary supplement market, tentatively aiming for a product launch this fall...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS101945

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel